ECLIPSE investigated whether OA provides better outcomes than conventional balloon angioplasty in calcified coronary lesions. An analysis of PROTECTED TAVR trial highlighted potential regional differences in the efficacy of CEP during TAVR. Sirolimus-coated balloons are non-inferior to paclitaxel-coated balloons in patients with femoropopliteal artery disease.